Adynxx, Inc. (ADYX)

Market Cap	581.00 +9,583.3%
Revenue (ttm)	n/a
Net Income	-10.57M
EPS	-1.82
Shares Out	5.81M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,300
Open	0.0002
Previous Close	0.0001
Day's Range	0.0001 - 0.0002
52-Week Range	0.000001 - 0.0002
Beta	-53.39
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Adynxx

Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 6
• Stock Exchange: OTCMKTS
• Ticker Symbol: ADYX

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 12, 2026

Data Sources Report a data error